NASDAQ:LMAT - LeMaitre Vascular Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding LeMaitre Vascular Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $30.74 +0.09 (+0.29 %) (As of 02/20/2020 04:00 PM ET) Add Compare Today's Range$30.49Now: $30.74▼$31.0050-Day Range$28.50MA: $34.86▼$38.4952-Week Range$25.39Now: $30.74▼$38.64Volume118,200 shsAverage Volume135,526 shsMarket Capitalization$614.52 millionP/E Ratio34.93Dividend Yield1.11%Beta1.23 ProfileAnalyst RatingsAdvanced ChartDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:LMAT Previous Symbol CUSIPN/A CIK1158895 Webhttp://www.lemaitre.com/ Phone781-221-2266Debt Debt-to-Equity RatioN/A Current Ratio4.42 Quick Ratio2.52Price-To-Earnings Trailing P/E Ratio34.93 Forward P/E Ratio33.05 P/E Growth3.89 Sales & Book Value Annual Sales$117.23 million Price / Sales5.24 Cash Flow$1.11 per share Price / Cash Flow27.76 Book Value$7.41 per share Price / Book4.15Profitability EPS (Most Recent Fiscal Year)$0.88 Net Income$17.93 million Net Margins15.30% Return on Equity12.85% Return on Assets10.58%Miscellaneous EmployeesN/A Outstanding Shares19,991,000Market Cap$614.52 million Next Earnings Date5/6/2020 (Estimated) OptionableOptionable Receive LMAT News and Ratings via Email Sign-up to receive the latest news and ratings for LMAT and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:LMAT Rates by TradingView LeMaitre Vascular (NASDAQ:LMAT) Frequently Asked Questions What is LeMaitre Vascular's stock symbol? LeMaitre Vascular trades on the NASDAQ under the ticker symbol "LMAT." How often does LeMaitre Vascular pay dividends? What is the dividend yield for LeMaitre Vascular? LeMaitre Vascular announced a quarterly dividend on Monday, February 10th. Stockholders of record on Tuesday, March 3rd will be given a dividend of $0.095 per share on Thursday, March 19th. This represents a $0.38 dividend on an annualized basis and a dividend yield of 1.24%. The ex-dividend date of this dividend is Monday, March 2nd. This is a boost from LeMaitre Vascular's previous quarterly dividend of $0.09. View LeMaitre Vascular's Dividend History. How were LeMaitre Vascular's earnings last quarter? LeMaitre Vascular Inc (NASDAQ:LMAT) released its quarterly earnings results on Thursday, February, 6th. The medical instruments supplier reported $0.23 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.23. The medical instruments supplier had revenue of $30.20 million for the quarter, compared to the consensus estimate of $30.44 million. LeMaitre Vascular had a net margin of 15.30% and a return on equity of 12.85%. The business's quarterly revenue was up 6.3% on a year-over-year basis. During the same period in the prior year, the firm earned $0.30 EPS. View LeMaitre Vascular's Earnings History. When is LeMaitre Vascular's next earnings date? LeMaitre Vascular is scheduled to release their next quarterly earnings announcement on Wednesday, May 6th 2020. View Earnings Estimates for LeMaitre Vascular. What guidance has LeMaitre Vascular issued on next quarter's earnings? LeMaitre Vascular updated its FY20 earnings guidance on Thursday, February, 6th. The company provided earnings per share (EPS) guidance of $0.90-$0.98 for the period, compared to the Thomson Reuters consensus estimate of $0.95. The company issued revenue guidance of $127.4-$130.8 million, compared to the consensus revenue estimate of $129.41 million. What price target have analysts set for LMAT? 4 brokers have issued 12-month target prices for LeMaitre Vascular's stock. Their forecasts range from $38.00 to $40.00. On average, they anticipate LeMaitre Vascular's stock price to reach $39.33 in the next year. This suggests a possible upside of 28.0% from the stock's current price. View Analyst Price Targets for LeMaitre Vascular. What is the consensus analysts' recommendation for LeMaitre Vascular? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for LeMaitre Vascular in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for LeMaitre Vascular. What are Wall Street analysts saying about LeMaitre Vascular stock? Here are some recent quotes from research analysts about LeMaitre Vascular stock: 1. According to Zacks Investment Research, "LeMaitre Vascular, Inc. is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects the people worldwide. LeMaitre develops, manufactures, and markets disposable and implantable vascular devices to address the needs of vascular surgeons and interventionalists. LeMaitre's diversified product portfolio consists of twelve well-known brand name products used in arteries and veins outside of the heart and are supported by a growing, specialized and highly trained organization of vascular sales professionals. LeMaitre Vascular offers a wide range of innovative products to vascular surgeons and interventionalists for improving procedure efficacy and minimizing patient recovery time. " (2/12/2020) 2. Barrington Research analysts commented, "We are maintaining our OUTPERFORM investment rating on LMAT shares and are increasing our price target to $32 (from $30 previously) given the encouraging organic growth (and particularly the strong unit volume growth). We think margins will expand meaningfully (vs. Q1) for the remainder of FY/19 and step up again in FY/20 as recently-hired sale reps become increasingly productive. We arrive at our target by attaching a 20x multiple to our 2019 adjusted EBITDA estimate. We assume approximately $60 million in net cash 12 months from now." (5/2/2019) Has LeMaitre Vascular been receiving favorable news coverage? News articles about LMAT stock have trended somewhat negative on Thursday, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. LeMaitre Vascular earned a media sentiment score of -1.4 on InfoTrie's scale. They also assigned media stories about the medical instruments supplier a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for LeMaitre Vascular. Who are some of LeMaitre Vascular's key competitors? Some companies that are related to LeMaitre Vascular include Irhythm Technologies (IRTC), Merit Medical Systems (MMSI), Inspire Medical Systems (INSP), AtriCure (ATRC), Cardiovascular Systems (CSII), Silk Road Medical (SILK), Atrion (ATRI), Tactile Systems Technology (TCMD), Shockwave Medical (SWAV), Luminex (LMNX), Axonics Modulation Technologies (AXNX), Cryolife (CRY), Intersect ENT (XENT), Orthofix Medical (OFIX) and Orthopediatrics (KIDS). What other stocks do shareholders of LeMaitre Vascular own? Based on aggregate information from My MarketBeat watchlists, some companies that other LeMaitre Vascular investors own include Canopy Growth (CGC), AbbVie (ABBV), Sociedad Quimica y Minera de Chile (SQM), Gilead Sciences (GILD), NVIDIA (NVDA), Aurora Cannabis (ACB), Aurora Cannabis (ACBFF), Adobe (ADBE), Boeing (BA) and Teva Pharmaceutical Industries (TEVA). Who are LeMaitre Vascular's key executives? LeMaitre Vascular's management team includes the folowing people: Mr. George W. LeMaitre, Chairman & CEO (Age 54)Mr. David B. Roberts, Pres & Director (Age 55)Mr. Joseph P. Pellegrino Jr., CFO, Treasurer, Sec. & Director (Age 54)Mr. Trent G. Kamke, Sr. VP of Operations (Age 48)Dr. George D. LeMaitre, Founder and Chairman of Scientific Advisory Board (Age 85) Who are LeMaitre Vascular's major shareholders? LeMaitre Vascular's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Conestoga Capital Advisors LLC (8.58%), Janus Henderson Group PLC (3.31%), State Street Corp (3.28%), Copeland Capital Management LLC (2.76%), Principal Financial Group Inc. (2.67%) and Russell Investments Group Ltd. (2.24%). Company insiders that own LeMaitre Vascular stock include David B Roberts, George W Lemaitre, Joseph P Pellegrino Jr, Lawrence J Jasinski, Michael H Thomas and Trent G Kamke. View Institutional Ownership Trends for LeMaitre Vascular. Which institutional investors are selling LeMaitre Vascular stock? LMAT stock was sold by a variety of institutional investors in the last quarter, including Municipal Employees Retirement System of Michigan, THB Asset Management, Algert Global LLC, Bank of New York Mellon Corp, Oxford Asset Management LLP, Arizona State Retirement System, Conestoga Capital Advisors LLC and GW&K Investment Management LLC. Company insiders that have sold LeMaitre Vascular company stock in the last year include David B Roberts, George W Lemaitre, Joseph P Pellegrino Jr, Lawrence J Jasinski, Michael H Thomas and Trent G Kamke. View Insider Buying and Selling for LeMaitre Vascular. Which institutional investors are buying LeMaitre Vascular stock? LMAT stock was purchased by a variety of institutional investors in the last quarter, including Principal Financial Group Inc., Foundry Partners LLC, Russell Investments Group Ltd., Goldman Sachs Group Inc., Cadence Capital Management LLC, Aviva PLC, Wedge Capital Management L L P NC and State Street Corp. View Insider Buying and Selling for LeMaitre Vascular. How do I buy shares of LeMaitre Vascular? Shares of LMAT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is LeMaitre Vascular's stock price today? One share of LMAT stock can currently be purchased for approximately $30.74. How big of a company is LeMaitre Vascular? LeMaitre Vascular has a market capitalization of $614.52 million and generates $117.23 million in revenue each year. The medical instruments supplier earns $17.93 million in net income (profit) each year or $0.88 on an earnings per share basis. View Additional Information About LeMaitre Vascular. What is LeMaitre Vascular's official website? The official website for LeMaitre Vascular is http://www.lemaitre.com/. How can I contact LeMaitre Vascular? LeMaitre Vascular's mailing address is 63 SECOND AVENUE, BURLINGTON MA, 01803. The medical instruments supplier can be reached via phone at 781-221-2266. MarketBeat Community Rating for LeMaitre Vascular (NASDAQ LMAT)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 437 (Vote Outperform)Underperform Votes: 310 (Vote Underperform)Total Votes: 747MarketBeat's community ratings are surveys of what our community members think about LeMaitre Vascular and other stocks. Vote "Outperform" if you believe LMAT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LMAT will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/20/2020 by MarketBeat.com StaffFeatured Article: How much money do you need to begin day trading?
